Study guide
13.2 Medication Delivery Routes and Devices in Critical Illness
Board Certified Critical Care Pharmacist Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pathophysiology and Recognition of Critical Illness
1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness
2 Chapter 2: Medical Devices and Circulatory Support
2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care
3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management
3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation
4 Chapter 4: Vasoactive and Inotropic Therapy in Shock
4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock
5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)
5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness
6 Chapter 6: Cardiovascular Emergencies
6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias
7 Chapter 7: Pulmonary and Infectious Diseases in the ICU
7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU
8 Chapter 8: Neurocritical Care
8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury
9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies
9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy
10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition
10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral
11 Chapter 11: Quality, Safety, and Clinical Guidelines
11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions
12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine
12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management
13 Chapter 13: Treatment Planning and Care Coordination
13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education
13.2 Medication Delivery Routes and Devices in Critical Illness
Key Takeaways Explain This Topic AI
Medication delivery in the ICU is shaped by anatomic alterations (post-surgical anatomy, short bowel), altered GI motility, fasting status, and unreliable enteral absorption in shock; alternative routes (IV, sublingual, rectal, subcutaneous, intramuscular, inhaled) are selected per drug properties.
IV access choice (peripheral vs. central) depends on vesicant properties, pH, osmolarity, and duration; vasopressors, concentrated electrolytes, TPN, and vesicant chemotherapy require central access.
Smart infusion pumps with dose error reduction systems (DERS) and drug libraries reduce medication errors; pharmacist role includes library maintenance, hard/soft limits, and pump integration with CPOE.
Specialized delivery routes (intrathecal/epidural, intraosseous, intranasal, nebulized, intraperitoneal) each have unique considerations; intrathecal vincristine is fatal and requires explicit labeling and separation protocols.
Last updated: July 2026
- Medication Delivery Routes and Devices in Critical Illness
- Route Selection in the ICU
Route Indication Considerations
Oral/NG/NJ Functional GI tract Absorption affected by gastric pH, motility, fasting, surgery; check compatibility with feeding tube
Sublingual Rapid onset, first-pass avoidance Limited drug availability (nitroglycerin, lorazepam, buprenorphine)
- Rectal When PO not possible Acetaminophen, diazepam, levetiracetam available; unpredictable absorption
- IV bolus Immediate effect Risk of rapid vasodilation, hypotension, arrhythmia; max rates per drug
- IV infusion Continuous dosing, titration Smart pump required; central access for vesicants
- Subcutaneous Heparin prophylaxis, insulin Absorption impaired in shock/edema
- Intramuscular Limited in ICU Avoid in coagulopathic, edematous patients
- Inhaled Pulmonary delivery Bronchodilators, corticosteroids, prostacyclin; ventilator circuit considerations
- Epidural/intrathecal Analgesia, chemotherapy Strict sterility; preservative-free only
- Intraosseous (IO) Emergency access Any IV medication can be given; pain on infusion
Topical/transdermal Systemic or local effect Fentanyl, nitroglycerin, clonidine; absorption affected by perfusion
- Intraperitoneal Peritoneal dialysis, intraperitoneal chemo Strict sterile technique
- Anatomic Alterations and Delivery
Post-gastrectomy, Roux-en-Y, short bowel: rapid transit, reduced absorption surface; extended-release formulations often ineffective; prefer immediate-release and IV forms.
Ileostomy/colostomy: short colon reduces absorption of extended-release drugs.
Whipple, esophagectomy: feeding jejunostomy for post-pyloric delivery; medications must be liquid or crushable.
Tracheostomy: inhaled medications via trach; MDI with adapter.
Post-esophagectomy with gastric pull-through: dumping syndrome; small frequent feeds; reduced absorption of slowly absorbed drugs.
Altered GI Physiology in Critical Illness
Reduced gastric motility: opioids, sepsis, diabetes gastroparesis → delayed gastric emptying → erratic absorption. Use prokinetics (metoclopramide, erythromycin); convert to post-pyloric feeding.
Reduced splanchnic perfusion: shock reduces mucosal absorption; IV preferred until stable.
Altered gastric pH: PPIs reduce absorption of ketoconazole, atazanavir, enoxapargin; increased absorption of weak bases.
Fasting status: food-dependent absorption (e.g., cefuroxime axetil increases with food); tube feed interactions (phenytoin binds to enteral formula).
- IV Access and Drug Compatibility
- Choice of IV Access
Drug Property Access Required
Vesicant (norepinephrine, dopamine, potassium, calcium, chemotherapy) Central (or large-bore peripheral with careful monitoring)
- pH <5 or >9 Central
- Osmolarity >600 mOsm/L Central
- TPN Central (dedicated lumen)
- Concentrated dextrose >10% Central
- Phlebitis-causing (amiodarone, vancomycin, potassium) Central preferred
- Y-Site Compatibility
Compatibility charts must be checked; examples of incompatible Y-site combinations:
Ceftriaxone + calcium-containing fluids (fatal precipitate).
Phenytoin + dextrose (crystallizes; use NS only).
Amiodarone + heparin (precipitate).
Pantoprazole + iron (precipitate).
- Smart Infusion Pumps and DERS
- Dose Error Reduction Systems
Hard limits: cannot be overridden without pharmacy approval (e.g., heparin >2x upper limit).
Soft limits: can be overridden with documented reason (e.g., norepinephrine titration above protocol max).
Drug library: per clinical area (ICU, OR, ED, general floor).
Smart pump interoperability: integration with CPOE and MAR to auto-populate infusion parameters reduces 50% of pump programming errors.
Pharmacist Role
Quarterly drug library review and update.
Set hard/soft limits per institutional protocol.
Review intercepted errors and adjust limits.
Education on pump library selection at shift change.
Inhaled Medication Delivery in Mechanically Ventilated Patients
MDI with chamber adapter: 4-10x recommended dose due to deposition in circuit; preferred for ventilated patients.
Nebulizer: continuous output; interrupts ventilator circuit (infection risk).
Particle size: 1-5 microns reaches lower airway.
Bronchodilators, corticosteroids, antibiotics (tobramycin, colistin), prostacyclin, heparin (inhalation injury).
Intrathecal and Epidural Delivery
Intrathecal: baclofen for spasticity, methotrexate/cytarabine for CNS leukemia, bupivacaine/opioid for analgesia.
Epidural: bupivacaine, fentanyl, hydromorphone for post-op analgesia.
NEVER give vincristine intrathecally — universally fatal within days. Tall man lettering (VINCRISTine) and dedicated preparation areas required.
Intraosseous (IO) Access
Emergency access when IV cannot be established within 90 seconds.
Any IV medication, including blood products and vasopressors, can be given IO.
Sites: proximal humerus, proximal tibia, distal tibia, sternum.
Bolus with 10 mL NS to clear marrow; rapid infusion may cause pain.
Replace with IV as soon as possible.
Special Delivery Devices
Patient-controlled analgesia (PCA): with dosing limits; pharmacist-programmed.
Patient-controlled analgesia with basal infusion: high-risk for opioid naive; avoid.
Ambulatory elastomeric pumps: home antibiotic infusions.
Implantable pumps: intrathecal baclofen, intrathecal pumps for pain/spasticity.
Closed-loop systems: artificial pancreas, automated anesthesia delivery; emerging.
Clinical Scenario
A patient with septic shock on four vasopressors via peripheral IVs develops norepinephrine extravasation at a peripheral site. The forearm is pale, cold, and painful. What is the appropriate intervention?
Answer: Stop the infusion immediately. Leave cannula in place and aspirate. Administer phentolamine 5-10 mg in 10 mL NS subcutaneously around the extravasation site using a 25-gauge needle, infiltrating in a circular pattern (alpha-blockade reverses ischemia). Apply warm compresses (alpha-agonist extravasation). Avoid cold compresses (worsen vasoconstriction). Document the event, monitor for necrosis, surgical consult if no improvement within 12-24h. Convert all other vasopressors to central access urgently.